IT
ITI Pharma and Healthcare Fund Direct Growth
Latest NAV
+12.44% 1Y
Sign In to Add to Portfolio
Benchmark: NIFTY Healthcare TRI
Expense ratio
0.92%
AUM
₹276 Cr
Min SIP
₹500
Min lump sum
₹5,000
1Y
+12.44%
3Y (ann.)
+18.88%
5Y (ann.)
+0.00%
Launched
Nov 2021
Where the NAV sits & how risky it is
₹19.43
52-week range
at 80%
₹19.43
Low 29 Jan 2026₹15.79
High 23 Sep 2026₹20.32
Risk level
Very High
Low
Very high
NAV history
11 Nov 2021
Since inception
01 Oct 2026
Returns by period
1W
-3.69%
1M
-3.02%
3M
+2.49%
6M
+20.12%
1Y
+12.44%
3Y
+18.88%
5Y
+0.00%
3Y and 5Y returns are annualised.
Return calculator
You invest
—
Est. gain
—
Est. value
—
Invested Gain
Invested
Projected value
min SIP ₹500
Estimate only. It assumes the selected past return repeats every year; 3Y and 5Y figures are taken as annualised. Actual returns vary and are not guaranteed.
Where your money goes
AS OF 31 MAY 2026
Equity 98.01%
Cash & other 1.99%
Sector split
Country split
Top 5 hold 38.8%
Top 10 hold 58.9%
40 equity holdings
Equity holdings
(top 30)
| # | Holding | Sector | Country | Weight | YTD |
|---|---|---|---|---|---|
| 1 | Sun Pharmaceutical
INE044A01036 |
Healthcare Drug Manufacturers - Specialty & Generic |
India |
14.25%
|
+5.76% |
| 2 | Divis Laboratories
INE361B01024 |
Healthcare Drug Manufacturers - Specialty & Generic |
India |
8.43%
|
+3.84% |
| 3 | Apollo Hospitals
INE437A01024 |
Healthcare Medical Care Facilities |
India |
6.20%
|
+20.81% |
| 4 | Laurus Labs
INE947Q01028 |
Healthcare Drug Manufacturers - Specialty & Generic |
India |
5.06%
|
+25.95% |
| 5 | Torrent Pharmaceuticals
INE685A01028 |
Healthcare Drug Manufacturers - Specialty & Generic |
India |
4.90%
|
+19.72% |
| 6 | Max Healthcare Institute
INE027H01010 |
Healthcare Medical Care Facilities |
India |
4.90%
|
-3.12% |
| 7 | Aurobindo Pharma
INE406A01037 |
Healthcare Drug Manufacturers - Specialty & Generic |
India |
4.28%
|
+24.50% |
| 8 | Dr Reddys Laboratories
INE089A01031 |
Healthcare Drug Manufacturers - Specialty & Generic |
India |
3.98%
|
+0.31% |
| 9 | Lupin
INE326A01037 |
Healthcare Drug Manufacturers - Specialty & Generic |
India |
3.53%
|
+8.71% |
| 10 | Cipla
INE059A01026 |
Healthcare Drug Manufacturers - Specialty & Generic |
India |
3.42%
|
-7.21% |
About this scheme
The investment objective of the scheme is to seek to generate long term capital appreciation through investing in equity and equity related securities of companies engaged in Pharma and Healthcare. However, there can be no assurance that the investment objective of the scheme would be achieved.
Fund manager(s): Nilay Dalal, Animesh Singh
Exit load: Exit load of 0.50%, if redeemed within 3 months.
Scheme snapshot
VR Rating
MS Rating
Plan
Growth
Type
DIRECT
Inception
11 Nov 2021
Lump-sum min
₹5,000
SIP
Purchase
Switch
STP
SWP
Similar schemes
RANKED BY 1Y RETURN
Nippon India Taiwan Equity Fund Direct Growth
1▲ 109.1 pts ahead of this fund
Franklin Asian Equity Fund Direct Growth
2▲ 20.9 pts ahead of this fund
Nippon India Japan Equity Fund - Direct Plan - Growth Plan - Bonus Option
3▲ 18.2 pts ahead of this fund
Nippon India Japan Equity Fund Direct Growth
4▲ 18.2 pts ahead of this fund
Bank of India Small Cap Fund Direct Growth
5▲ 16.8 pts ahead of this fund
TRUSTMF Small Cap Fund Direct Growth
6▲ 16.7 pts ahead of this fund